Vericel Co. (NASDAQ:VCEL) Director Robert L. Md Zerbe Sells 2,500 Shares of Stock

Vericel Co. (NASDAQ:VCEL) Director Robert L. Md Zerbe sold 2,500 shares of the stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $60.00, for a total transaction of $150,000.00. Following the transaction, the director now owns 26,595 shares in the company, valued at approximately $1,595,700. This represents a 8.59 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Vericel Stock Down 0.8 %

VCEL stock opened at $58.62 on Tuesday. The stock has a market capitalization of $2.89 billion, a PE ratio of 977.00 and a beta of 1.66. Vericel Co. has a 52 week low of $32.31 and a 52 week high of $61.49. The firm has a 50 day moving average of $46.41 and a 200 day moving average of $47.07.

Vericel (NASDAQ:VCEL) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.03. The firm had revenue of $57.91 million for the quarter, compared to analyst estimates of $55.32 million. Vericel had a net margin of 1.56% and a return on equity of 1.48%. On average, equities research analysts expect that Vericel Co. will post 0.13 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts have issued reports on VCEL shares. Canaccord Genuity Group began coverage on Vericel in a research report on Friday, August 9th. They set a “buy” rating and a $57.00 target price on the stock. StockNews.com upgraded Vericel from a “sell” rating to a “hold” rating in a research note on Friday, November 8th. Canaccord Genuity Group reissued a “buy” rating and set a $60.00 price target on shares of Vericel in a research report on Tuesday, November 19th. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Vericel in a research report on Friday, November 8th. Finally, TD Cowen increased their target price on shares of Vericel from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Tuesday, August 27th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Vericel presently has an average rating of “Moderate Buy” and a consensus price target of $58.14.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of VCEL. Vanguard Group Inc. raised its position in Vericel by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 3,413,442 shares of the biotechnology company’s stock worth $177,567,000 after buying an additional 39,349 shares during the last quarter. CANADA LIFE ASSURANCE Co raised its holdings in shares of Vericel by 7.8% during the first quarter. CANADA LIFE ASSURANCE Co now owns 58,377 shares of the biotechnology company’s stock worth $3,036,000 after purchasing an additional 4,227 shares during the last quarter. Advisors Asset Management Inc. boosted its holdings in Vericel by 25.7% in the first quarter. Advisors Asset Management Inc. now owns 16,508 shares of the biotechnology company’s stock valued at $859,000 after purchasing an additional 3,374 shares during the last quarter. Lazard Asset Management LLC boosted its holdings in Vericel by 178.7% in the first quarter. Lazard Asset Management LLC now owns 2,584 shares of the biotechnology company’s stock valued at $134,000 after purchasing an additional 1,657 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in Vericel by 6.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 27,280 shares of the biotechnology company’s stock worth $1,420,000 after purchasing an additional 1,721 shares during the period.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.